Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Catheter Connections' vascular access disinfecting cap gets US clearance

This article was originally published in Clinica

Executive Summary

The US FDA has granted 510(k) clearance for DualCap, a device developed by Catheter Connections (Salt Lake City, Utah) to disinfect IV access points, the needleless injection site (NIS) and the male luer – a type of connector fitting – at the end of the IV tubing. Patients contract catheter-related bloodstream infections when microbes enter the bloodstream in one of two ways. The less prevalent route is from the skin at the catheter insertion site. The more common route is intraluminal contamination, when the two primary IV access points, the NIS and the male luer, become contaminated. There are nearly 500,000 cases every year with a 12-25% mortality rate in the US. DualCap will go on sale in the US in the second half of 2010.

You may also be interested in...



Normality Reasserts Itself For Biotech IPOs

The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.

MRM Health Pulls A Pouchitis Hit Out Of The Bag

The mid-stage success is encouraging, but taking on Takeda won’t be easy.

Novartis Draws Out Its APPLAUSE

Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT095132

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel